We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

By LabMedica International staff writers
Posted on 23 Oct 2026

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. More...

However, individual risks can vary substantially even among patients considered clinically high risk, complicating decisions about additional therapy. To refine risk assessment within this group, a newly evaluated digital slide-based test combines routine pathology images with clinicopathological data to provide prognostic classification.

Spotlight Medical’s (Paris, France) myStage Dx is a software-only in vitro diagnostic medical device that assesses recurrence risk in this patient population. It combines analysis of a digitized histopathology slide with routinely available clinicopathological data to generate a prognostic classification for qualified healthcare professionals. The device holds CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (EU-IVDR).

Its prognostic performance was assessed in an independent, blinded evaluation using data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dx predictions were generated without access to clinical outcomes. Researchers at Karolinska Institutet in Sweden then linked the predictions to patient outcomes and independently evaluated performance according to a prespecified protocol and statistical analysis plan. The findings build on earlier evidence from the CANTO and UNIRAD trial cohorts, published in the Journal of Clinical Oncology in 2025.

Within the clinically high-risk PANTHER population, myStage Dx distinguished two groups with different long-term outcomes. The Low Risk group accounted for 23.5% of patients, with an estimated 96.1% alive and free from breast cancer recurrence at ten years, compared with 76.6% in the Not Low Risk group. This difference remained statistically significant after adjustment for standard clinicopathological prognostic factors.

The PANTHER patients received chemotherapy and endocrine therapy without cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The results identify a subgroup with favorable long-term outcomes under those treatment conditions. Treatment discussions should consider individual recurrence risk, the expected benefits and risks of additional treatment, and patient preferences, consistent with American Society of Clinical Oncology (ASCO) guidance.

“Confidence in a clinical test has to be earned through independent scrutiny. We chose a blinded evaluation of myStage Dx by an independent research team, accepting that the results were outside our control. These findings are consistent with our previous studies and reinforce the test’s ability to address a concrete clinical problem: identifying patients with a favorable prognosis despite clinically high-risk disease, with a clear risk classification to inform treatment discussions,” said Dr. Marvin Lerousseau, co-founder and chief scientific officer of Spotlight Medical.

“As ASCO guidelines highlight, accurately assessing recurrence risk is essential to treatment decisions. For patients, additional therapies can mean up to three more years of treatment, with side effects, anxiety, and a real impact on daily life. We are proud to show how myStage Dx can help oncologists better assess individual risk and support more informed clinical decisions, with the aim of improving patient care,” said Sylvain Berlemont, co-founder and chief executive officer of Spotlight Medical.

Related Links
Spotlight Medical
Karolinska Institutet


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Molecular Diagnostics

view channel
Image: A blood test measuring circulating tumor DNA may help identify men with hormone-resistant oligoprogressive prostate cancer most likely to benefit from stereotactic body radiotherapy (Image Credit: Adobe Stock)

Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer

Advanced prostate cancer can progress despite hormone-based treatment, with imaging sometimes revealing only limited areas of active disease. For men with hormone-resistant oligoprogressive prostate cancer,... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.